Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.46 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352243 | 0.89 | PTGER4 (0.58) | PTGER4 | |
| SCHEMBL5352209 | 0.88 | PTGER4 (0.59) | PTGER4 | |
| SCHEMBL5352224 | 0.88 | PTGER4 (0.58) | PTGER4 | |
| SCHEMBL5351605 | 0.86 | PTGER4 (0.49) | PTGER4PTGER3 | |
| SCHEMBL5352233 | 0.85 | PTGER4 (0.49) | PTGER4 | |
| SCHEMBL14569820 | 0.80 | PTGER4 (0.42) | PTGER4FNTAFNTBPTGER3 | |
| SCHEMBL6339372 | 0.79 | PTGER4 (0.46) | PTGER4PTGER3 | |
| SCHEMBL6347395 | 0.78 | PTGER4 (0.51) | PTGER4PTGER3 | |
| SCHEMBL5350571 | 0.78 | PTGER4 (0.75) | PTGER4 | |
| SCHEMBL6346170 | 0.77 | KDM4E (0.41) | PTGER4CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-01 | — | — | US | claimed |
| EP-1314719-A1 | BENZOIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-28 | — | — | EP | claimed |
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
| EP-1314719-A1 | BENZOIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | PTGER1, PTGER4, PTGES | PTGER4 2/4885LARS1 4628/4885FLT1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.